The studies, to be presented at a cardiologist meeting Sunday, are centered around whether Plavix and other blood-thinning drugs should play a greater role in treating high-risk heart patients before, during and following heart attacks. The studies could provide a boost to newer drugs, but also could revive stagnated sales of older blood-thinning drugs.

Full Story:

Related Summaries